What is GLP-1 Ozempic?
Ozempic — the brand name for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Denmark-based Novo Nordisk — has become one of the most talked-about prescription drugs in American healthcare history. Originally approved by the US Food and Drug Administration (FDA) in 2017 solely for the management of Type 2 diabetes in adults, Ozempic works by mimicking the naturally occurring GLP-1 hormone, which triggers insulin release from the pancreas, suppresses glucagon secretion, slows the rate at which food moves through the stomach, and signals the brain’s satiety centers to reduce hunger. What began as a carefully controlled diabetes treatment rapidly evolved into something far broader — a cultural phenomenon that spilled across tabloid pages, social media feeds, and primetime news as reports of dramatic weight loss among users, including high-profile celebrities, turned Ozempic into a household name. By 2020, prescriptions for GLP-1 drugs across the US had already begun climbing at a pace the pharmaceutical market had rarely seen before, and that trajectory has not slowed even slightly heading into 2026.
The story of GLP-1 medications in 2026 is not just about one drug. It is about a category of treatments — spanning Wegovy (the FDA-approved obesity formulation of semaglutide), Mounjaro and Zepbound (tirzepatide, made by Eli Lilly), Rybelsus (oral semaglutide), and several others — that have collectively reshaped American conversations about obesity, Type 2 diabetes, cardiovascular disease, and even chronic kidney disease. As of November 2025, a KFF Health Tracking Poll found that approximately 1 in 8 US adults — roughly 12% of the adult population, equivalent to more than 30 million Americans — say they are currently taking a GLP-1 drug. An even larger share, nearly 1 in 5 (18%), say they have taken one at some point in their life. The global GLP-1 receptor agonist market was valued at $53.46 billion in 2024 and is forecast to reach $156.71 billion by 2030, a growth curve that reflects not just blockbuster demand in the US, but rapid international expansion as well. For any website, researcher, or healthcare professional trying to understand exactly where things stand right now, this article brings together the most current, verified data available as of March 2026.
Key Facts About GLP-1 Ozempic in the US 2026
| Fact | Detail |
|---|---|
| FDA first approval of Ozempic (semaglutide) | December 5, 2017 — for Type 2 diabetes management in adults |
| FDA approval for cardiovascular risk reduction | 2020 — reduces risk of heart attack, stroke, or death in T2D adults with heart disease |
| FDA approval for obesity (Wegovy/semaglutide) | June 2021 — same active ingredient as Ozempic at a higher dose |
| FDA approval for chronic kidney disease | January 2025 — reduces risk of worsening CKD and cardiovascular death in T2D adults |
| Share of Ozempic in the GLP-1 receptor agonist market | 37.77% market share in 2025 — largest single brand share |
| US adults currently taking a GLP-1 drug (Nov 2025) | ~12% (1 in 8 adults); approximately 30+ million Americans |
| US adults who have ever taken a GLP-1 drug (Nov 2025) | ~18% (nearly 1 in 5 adults) |
| GLP-1 prescriptions growth since 2020 | More than tripled between 2020 and 2025 |
| GLP-1 prescriptions for obesity/overweight (2019–2024) | Rose 587% from 2019 to 2024 (FAIR Health, 2025) |
| Non-diabetic adults prescribed GLP-1 (2019–2024) | Jumped 1,961% during the same period (FAIR Health, 2025) |
| Ozempic spending growth (2018–2023) | From $410 million in 2018 to $26.42 billion by 2023 |
| Global GLP-1 market value (2024) | $53.46 billion |
| Global GLP-1 market projection (2030) | $156.71 billion (CAGR of 17.46%) |
| Novo Nordisk 2024 total net sales | ~$42.13 billion (25% year-over-year increase) |
| Ozempic injectable 2024 sales (Novo Nordisk) | ~$17.46 billion |
| US obesity rate decline (2022–2025) | Dropped from 39.9% (2022) to 37.0% (2025) — approximately 7.6 million fewer obese adults |
| US adults aware of weight loss injectables (2025) | 89% — up from 80% the prior year (Gallup, 2025) |
| GLP-1 drug discontinuation rate within 1 year | 50–75% of users stop within the first 12 months |
Source: FDA; KFF Health Tracking Poll (November 2025); RAND Corporation (August 2025); FAIR Health (May 2025); AMA / JAMA Network Open (2025); Novo Nordisk SEC filings (2024, 2025); Gallup National Health and Well-Being Index (October 2025); Grand View Research; CDC National Health Interview Survey 2024
The statistics above tell a story of pharmaceutical history being made in real time. The 1,961% surge in non-diabetic adults being prescribed GLP-1 drugs between 2019 and 2024 is one of the most striking numbers in modern medicine — it reflects a wholesale reimagining of how physicians, patients, and insurers are approaching obesity as a chronic disease rather than a personal failing. The 587% rise in GLP-1 prescriptions for overweight and obesity over the same five-year period drove demand so far past available supply that the FDA was forced to authorize compounded semaglutide from third-party pharmacies — a decision that sparked well over 100 lawsuits from Novo Nordisk before being reversed in early 2025 when the FDA formally ended the shortage designation.
What is equally striking is the speed of public awareness. The Gallup survey finding that 89% of US adults were aware of weight loss injectables by 2025 — compared to just 19% in July 2023 who said they knew “a lot” about these drugs — is a cultural shift that no amount of pharmaceutical marketing spend alone can explain. The combination of celebrity admissions, social media content, physician endorsements, and genuine clinical outcomes stories created the rarest of pharmaceutical phenomena: an organic, word-of-mouth demand curve for a prescription injectable drug. And as the market data confirms, the financial rewards for Novo Nordisk have been extraordinary — Ozempic alone generated approximately $17.46 billion in revenue in 2024, up from just $410 million six years earlier in 2018.
GLP-1 Ozempic User Statistics in the US 2026
| User Category | Data Point | Source |
|---|---|---|
| US adults currently taking a GLP-1 drug | ~12% of all adults (KFF, Nov 2025); ~15 million actively using (CNN / KFF) | KFF / CNN |
| US adults who have ever taken a GLP-1 drug | ~18% — nearly 1 in 5 US adults | KFF Health Tracking Poll, Nov 2025 |
| RAND estimate of GLP-1 users (April–May 2025) | 11.8% of US adults (survey of 8,793 adults) | RAND Corporation, Aug 2025 |
| Adults with Type 2 diabetes who used a GLP-1 | 57% have ever used; 45% currently using (KFF Nov 2025) | KFF, Nov 2025 |
| Diabetic adults using GLP-1 injectables (2024 NHIS) | 26.5% of all adults with diagnosed diabetes — ~6.9 million people | CDC / NCHS, 2024 |
| T2D patients with active GLP-1 Rx (2022–mid-2024) | ~1 in 5 of 6 million-plus T2D patients identified in EHR data | HealthVerity Marketplace, 2025 |
| Adults with heart disease who used GLP-1 | 40% have ever used; 29% currently using | KFF, Nov 2025 |
| Adults diagnosed obese/overweight using GLP-1 | 22% say they have used or are currently using | KFF / Creo Clinic |
| GLP-1 use by age group — highest prevalence | Adults aged 50–64: 22% currently using (KFF Nov 2025) | KFF, Nov 2025 |
| GLP-1 use among adults 65+ | Only 9% currently using — attributed to Medicare coverage gap | KFF, Nov 2025 |
| Women vs. men currently using GLP-1 | 15% of women vs. 9% of men currently using | KFF, Nov 2025 |
| Women aged 50–64 — RAND highest usage group | ~1 in 5 women aged 50–64 have used GLP-1 drugs | RAND Corporation, 2025 |
| Women aged 30–49 vs. men same age | Women more than twice as likely to have used a GLP-1 | RAND Corporation, 2025 |
| Total patients with GLP-1 prescriptions in HealthVerity data | Over 19.1 million patients with prescription records | HealthVerity Marketplace, 2025 |
| Novo Nordisk total patients reached (2025) | Nearly 46 million people benefiting from Novo Nordisk treatments globally | Novo Nordisk 2025 Annual Report (SEC) |
Source: KFF Health Tracking Poll (November 2025); CDC / NCHS National Health Interview Survey 2024; RAND Corporation (August 2025); HealthVerity Marketplace (2025); Novo Nordisk 2025 Annual Report (SEC Form 6-K)
The user data paints a vivid demographic picture of who exactly is taking GLP-1 drugs like Ozempic in America today. The CDC’s 2024 National Health Interview Survey, one of the most rigorous government data sources available, put the figure at 6.9 million adults with diagnosed diabetes using GLP-1 injectables — representing 26.5% of all diabetic adults in the country. But the KFF data, which captures broader self-reported use across both diabetic and non-diabetic populations, tells a bigger story: with 57% of adults diagnosed with diabetes saying they have tried a GLP-1 drug, and 40% of adults with heart disease reporting the same, these medications have clearly embedded themselves deep into chronic disease management in the United States.
The gender and age breakdown reveals a significant skew. Women are using these drugs at nearly double the rate of men among adults aged 30 to 49, and women aged 50 to 64 represent the single highest-usage demographic cohort identified by RAND’s nationally representative 2025 survey. The striking drop in usage among adults 65 and older — down to just 9% despite that age group carrying a disproportionately high burden of both diabetes and obesity — is almost entirely explained by Medicare’s prohibition on covering weight loss drugs, a policy that continues to generate fierce debate in healthcare policy circles as of early 2026.
GLP-1 Ozempic Revenue & Market Statistics in the US 2026
| Revenue / Market Category | Data Point | Source |
|---|---|---|
| Ozempic spending in 2018 | $410 million | AMA / JAMA Network Open (2025) |
| Ozempic spending in 2023 | $26.42 billion — representing a ~6,300% increase in 5 years | AMA / JAMA Network Open (2025) |
| Ozempic injectable sales in 2024 | ~$17.46 billion (120.34 billion DKK) | Novo Nordisk 2024 Annual Report (SEC) |
| Wegovy (obesity semaglutide) spending in 2021 | $580 million (first year of obesity approval) | AMA / JAMA Network Open (2025) |
| Wegovy spending in 2023 | $6.99 billion | AMA / JAMA Network Open (2025) |
| Mounjaro (tirzepatide) spending in 2022 | $2.51 billion (first year of T2D indication) | AMA / JAMA Network Open (2025) |
| Mounjaro spending in 2023 | $12.42 billion | AMA / JAMA Network Open (2025) |
| Novo Nordisk total net sales 2024 | ~$42.13 billion (290.4 billion DKK; +25% YoY) | Novo Nordisk 2024 Annual Report (SEC Form 6-K) |
| Novo Nordisk total net sales 2025 | ~$44.8 billion (309.1 billion DKK; +6% as reported / +10% CER) | Novo Nordisk 2025 Annual Report (SEC Form 6-K) |
| Novo Nordisk obesity care sales growth 2025 | +31% at constant exchange rates (CER) | Novo Nordisk 2025 Annual Report (SEC) |
| Novo Nordisk diabetes care sales growth 2025 | +4% at constant exchange rates (CER), driven by Ozempic | Novo Nordisk 2025 Annual Report (SEC) |
| Global GLP-1 receptor agonist market (2024) | $53.46 billion | Grand View Research / Creo Clinic |
| Global GLP-1 receptor agonist market projection (2030) | $156.71 billion (CAGR 17.46% from 2025–2030) | Grand View Research |
| Global GLP-1 drugs market size (2026) | $58.05 billion | Towards Healthcare / Precedence Research |
| Global GLP-1 drugs market projection (2035) | $132.79 billion (CAGR 9.63% from 2026–2035) | Towards Healthcare |
| North America share of global GLP-1 market (2025) | 76.19% of global GLP-1 receptor agonist revenue | Grand View Research |
| US share of North American GLP-1 weight loss market (2024) | 95.23% of the North American obesity GLP-1 segment | Grand View Research |
| Semaglutide share of GLP-1 weight loss market (2024) | 60.70% of the global GLP-1 weight loss drug segment | Grand View Research |
| Novo Nordisk market value peak (May 2024) | $570 billion — larger than the entire economy of Denmark | Creo Clinic / Novo Nordisk |
Source: AMA / JAMA Network Open (2025); Novo Nordisk SEC Form 6-K (2024 and 2025 annual reports); Grand View Research; Towards Healthcare / Precedence Research; Creo Clinic
The revenue trajectory of Ozempic and the broader GLP-1 market is arguably without precedent in the history of the pharmaceutical industry. Ozempic’s spending growth from $410 million in 2018 to $26.42 billion by 2023 — a roughly 6,300% increase in five years — comfortably outpaces any drug in recent memory. And yet the market appears to still be in an early growth phase. Novo Nordisk’s full-year 2025 revenues reached approximately $44.8 billion, up from $42.13 billion in 2024, with obesity care sales growing at 31% in constant exchange rates even as the company acknowledged headwinds from compounded semaglutide eating into its US market share. The 2025 court decision ending compounding pharmacy production of non-branded semaglutide — following Novo Nordisk’s wave of lawsuits — is expected to sharpen the company’s US revenue recovery in 2026.
At the macro level, the North American region holding 76.19% of global GLP-1 receptor agonist revenue in 2025 — with the US alone accounting for 95.23% of that North American share — underscores how overwhelmingly the American healthcare market continues to drive this category. The global GLP-1 drugs market standing at $58.05 billion in 2026, and forecast to grow to $132.79 billion by 2035, suggests that even after years of explosive growth, the industry believes the peak demand wave is still ahead — particularly as insurance coverage expands, oral formulations mature, and new indications beyond diabetes and obesity continue to be validated in clinical trials.
GLP-1 Ozempic Weight Loss Efficacy Statistics in the US 2026
| Efficacy / Outcomes Category | Data Point | Source |
|---|---|---|
| Semaglutide body weight reduction — clinical trial | 14.9% reduction in body weight over 68 weeks | SURMOUNT clinical trial data |
| Tirzepatide body weight reduction — clinical trial | 20.9% reduction in body weight over 72 weeks | SURMOUNT-5 trial |
| Tirzepatide vs semaglutide direct comparison (SURMOUNT-5) | Tirzepatide: ~20% weight loss (~50 lbs) vs. semaglutide ~14% (~33 lbs) | SURMOUNT-5 trial / HealthVerity |
| Semaglutide real-world weight loss (1 year) | 7.7% of body weight — roughly half of trial outcomes | 2025 study published in Obesity |
| Tirzepatide real-world weight loss (1 year) | 12.4% of body weight | 2025 study published in Obesity |
| Ozempic HbA1C reduction (0.5 mg dose) | 1.4% reduction in hemoglobin A1C levels | Novo Nordisk 2023 clinical data |
| Ozempic HbA1C reduction (1 mg dose) | 1.6% reduction in hemoglobin A1C levels | Novo Nordisk 2023 clinical data |
| Cardiovascular risk reduction (Ozempic — SELECT trial) | 20–25% reduction in major cardiovascular events | SELECT trial / HealthVerity |
| Bariatric surgeries decline (2019–2024) | Fell by nearly 42% as GLP-1 prescriptions surged | FAIR Health, May 2025 |
| US obesity rate (2022 peak) | 39.9% of US adults — highest recorded at that time | Gallup National Health and Well-Being Index |
| US obesity rate (2025) | 37.0% — a 2.9 percentage point decline since 2022 | Gallup National Health and Well-Being Index, Oct 2025 |
| Reduction in obese US adults (2022–2025) | Approximately 7.6 million fewer adults classified as obese | Gallup, Oct 2025 |
| GLP-1 usage for weight loss — doubled since early 2024 | Use of GLP-1 for weight loss grew from 5.8% to 12.4% of adults since Feb 2024 | Gallup, Oct 2025 |
| Diabetes diagnosis rate in US (2025) | 13.8% — highest ever recorded in Gallup surveys | Gallup National Health and Well-Being Index, Oct 2025 |
Source: SURMOUNT and SURMOUNT-5 clinical trials; 2025 study in Obesity journal (HealthVerity); Novo Nordisk 2023 prescribing data; SELECT cardiovascular trial; FAIR Health (May 2025); Gallup National Health and Well-Being Index (October 2025)
The clinical efficacy data behind semaglutide (Ozempic/Wegovy) is genuinely impressive, and the numbers from tirzepatide are even more so. The landmark SURMOUNT-5 trial — the first head-to-head comparison between the two leading GLP-1 agents — showed that tirzepatide achieved roughly 20% weight loss (approximately 50 pounds) compared to 14% weight loss (33 pounds) with semaglutide. That roughly six percentage point gap in clinical outcomes has shifted prescriber behavior meaningfully, with analysts noting that clinicians are increasingly defaulting to tirzepatide for new obesity-focused prescriptions where coverage allows. That said, real-world results tell a more tempered story: users on semaglutide lose an average of 7.7% of body weight in the first year outside clinical trial conditions, while tirzepatide users average 12.4% — both figures significantly below trial results, largely explained by early dropout rates and dose reductions.
Perhaps the most significant population-level signal heading into 2026 is the Gallup National Health and Well-Being Index’s October 2025 finding that the US adult obesity rate has dropped from its 2022 peak of 39.9% to 37.0% — representing approximately 7.6 million fewer Americans classified as obese in just three years. This is the first statistically significant sustained decline in US obesity in the modern era, and researchers at Gallup explicitly link it to the doubling of GLP-1 drug use for weight loss since early 2024. The 42% decline in bariatric surgeries between 2019 and 2024 further confirms that GLP-1 therapies have become the dominant clinical response to obesity — reshaping surgical volumes, endocrinology practices, and insurance coverage debates simultaneously.
GLP-1 Ozempic Demographics & Access Statistics in the US 2026
| Demographic / Access Category | Data Point | Source |
|---|---|---|
| GLP-1 use among Black US adults | 18% have taken GLP-1 medications | KFF / Creo Clinic |
| GLP-1 use among Hispanic US adults | 13% have taken GLP-1 medications | KFF / Creo Clinic |
| GLP-1 use among White US adults | 10% have taken GLP-1 medications | KFF / Creo Clinic |
| Hispanic adults with T2D using GLP-1 injectables (2024) | 31.3% — highest among racial/ethnic groups with diabetes | CDC / NCHS NHIS 2024 |
| Asian adults with T2D using GLP-1 injectables (2024) | 12.1% — lowest among racial/ethnic groups with diabetes | CDC / NCHS NHIS 2024 |
| GLP-1 use — adults with obesity-level BMI vs healthy weight | 32.4% (obesity BMI) vs. 16.7% (healthy weight BMI) among diabetics | CDC / NCHS NHIS 2024 |
| Monthly out-of-pocket cost without insurance | Up to $1,200/month for Ozempic; up to $1,300/month for Wegovy/Zepbound | GoodRx / AJMC |
| GLP-1 users paying full out-of-pocket (insured) | 27% of insured GLP-1 users still paid the full cost themselves | KFF, Nov 2025 |
| GLP-1 users who find them difficult to afford | 56% of all GLP-1 users (and 55% of those with insurance) | KFF, Nov 2025 |
| Users who stopped due to cost | 14% of GLP-1 users stopped because of drug cost | KFF, Nov 2025 |
| Users who stopped due to side effects | 13% of GLP-1 users cited side effects as reason for stopping | KFF, Nov 2025 |
| Medicare coverage for weight loss GLP-1s | Not covered as of 2026 for pure weight loss indication | American College of Gastroenterology, April 2025 |
| GLP-1 prescriptions among adults 18–39 (2019–2024) | Rose from 0.19% to 1.33% — a 588% increase | FAIR Health, May 2025 |
| Patients sourcing GLP-1 from primary care or specialist | ~80% of GLP-1 users got prescriptions from a doctor/specialist | KFF survey |
| Patients sourcing GLP-1 from online providers | ~11% obtained GLP-1 from an online provider or website | KFF survey |
| Non-diabetic patients with GLP-1 Rx (2020–2023) | ~1 in 4 of 1.5 million GLP-1 patients did not carry a T2D diagnosis | HealthVerity Marketplace |
Source: CDC / NCHS National Health Interview Survey 2024; KFF Health Tracking Poll (November 2025); FAIR Health (May 2025); GoodRx; AJMC (September 2025); HealthVerity Marketplace (2025); American College of Gastroenterology (April 2025)
The demographic access data for GLP-1 drugs like Ozempic in 2026 exposes a complex and sometimes counterintuitive landscape. Black adults in the US actually report the highest overall GLP-1 usage rate at 18% — higher than White adults at 10% and Hispanic adults at 13%. But the CDC’s 2024 NHIS data reveals a significant disparity within the diabetic population, where Asian adults with diabetes use GLP-1 injectables at just 12.1% — less than half the rate of Hispanic adults at 31.3%. These disparities likely reflect a combination of physician prescribing patterns, access to specialty care, insurance coverage variation, and cultural factors around injectable medications.
The cost and affordability crisis is the single biggest access barrier in the GLP-1 market as of 2026. With Ozempic costing up to $1,200 per month out-of-pocket and Wegovy or Zepbound reaching $1,300 monthly without insurance, these are among the most expensive maintenance medications in the US pharmaceutical landscape. The KFF finding that 56% of GLP-1 users — including 55% of those with insurance coverage — still find these drugs difficult to afford makes clear that even having insurance doesn’t fully solve the problem. Medicare’s ongoing refusal to cover GLP-1 drugs for pure weight loss creates a hard ceiling on access for the over-65 population, which is why that cohort’s usage rate (9%) remains dramatically below the national average despite carrying among the highest rates of obesity and diabetes of any age group.
GLP-1 Ozempic Side Effects & Discontinuation Statistics in the US 2026
| Side Effects / Discontinuation Category | Data Point | Source |
|---|---|---|
| Users experiencing at least one side effect | More than 48% of Ozempic users experience at least one side effect | JAMA Network Open, 2022 |
| Most common side effect — nausea | ~37–50% of GLP-1 users report nausea (clinical trials: ~37%; RAND 2025: ~50%) | JAMA / RAND 2025 |
| Diarrhea prevalence among GLP-1 users | ~33% report diarrhea (RAND 2025); ~9% per Ozempic clinical trials | RAND 2025 / JAMA Network Open |
| Vomiting prevalence among GLP-1 users | About 1 in 5 (20%) of GLP-1 users reported vomiting | RAND Corporation, Aug 2025 |
| Constipation and abdominal pain | ~5% of Ozempic users in clinical trials | JAMA Network Open, 2022 |
| Discontinuation due to GI adverse reactions (Ozempic 0.5mg) | 3.1% in placebo-controlled trials (vs. 0.4% for placebo) | FDA / Novo Nordisk prescribing information |
| Discontinuation due to GI adverse reactions (Ozempic 1mg) | 3.8% in placebo-controlled trials | FDA / Novo Nordisk prescribing information |
| Overall GLP-1 discontinuation rate within 1 year | 50–75% of users stop within 12 months (multiple studies) | Northwestern Medicine JAMA Viewpoint, 2024; RAND 2025 |
| Semaglutide early discontinuation rate (2025 study) | ~22% of semaglutide users stopped within the first year | 2025 study published in Obesity |
| Tirzepatide early discontinuation rate (2025 study) | ~16% stopped within the first year | 2025 study published in Obesity |
| Wegovy/Zepbound persistence at 1 year (2024 start cohort) | 63% of patients starting in early 2024 still on therapy at 1 year | Prime Therapeutics pharmacy analysis (2025) |
| Wegovy/Zepbound persistence at 1 year (2023 start cohort) | 40% of patients starting in 2023 still on therapy at 1 year | Prime Therapeutics pharmacy analysis (2025) |
| Wegovy persistence at 3 years | Only 14% of Wegovy users remain on the drug after 3 years | Prime Therapeutics pharmacy analysis (2025) |
| Weight regain after stopping | Majority of users who discontinue regain lost weight | Northwestern Medicine / Healthline |
| Users who stopped — interest drops when informed of weight regain | Interest in GLP-1 use fell from 45% to 14% when regain risk was explained | 2023 survey cited by Northwestern Medicine JAMA Viewpoint |
| Psychiatric medication history — discontinuation link | People with psychiatric medication history 12% more likely to stop within year 1 | AJMC / EASD 2025 study |
Source: JAMA Network Open (2022); FDA / Novo Nordisk prescribing information; RAND Corporation (August 2025); 2025 study published in Obesity journal; Prime Therapeutics pharmacy analysis (2025); Northwestern Medicine JAMA Viewpoint (November 2024); AJMC / European Association for the Study of Diabetes (EASD) Annual Meeting (September 2025)
The side effect and discontinuation data for GLP-1 drugs including Ozempic is one of the most important and underreported dimensions of this story. The headline figure — that 50–75% of users stop taking GLP-1 drugs within the first 12 months — was described in a 2024 JAMA Viewpoint from Northwestern Medicine cardiologist Dr. Sadiya Khan as a “staggeringly high discontinuation rate” that “should raise alarms for clinicians, policy makers, and public health experts.” The RAND Corporation’s 2025 nationally representative survey adds important texture to this: approximately half of all GLP-1 users reported experiencing nausea, one-third reported diarrhea, and one-fifth reported vomiting — the gastrointestinal side effect profile that clinical trials predicted but that real-world users encounter with notable frequency. The FDA’s own prescribing data confirms that 3.1% to 3.8% of Ozempic users in placebo-controlled trials discontinued specifically because of GI adverse reactions.
The persistence data from Prime Therapeutics’ 2025 pharmacy claims analysis is particularly sobering. While the 1-year retention rate improved from 40% (2023 cohort) to 63% (2024 cohort) — a genuine improvement driven by easing drug shortages, better insurance coverage, and improved side effect management protocols — the 3-year persistence rate for Wegovy users sits at just 14%. This means that within three years, 86% of people who start Wegovy will have stopped taking it, and the medical literature is unambiguous that most will regain a substantial portion of the weight they lost. As prescribers and policymakers increasingly grapple with GLP-1 drugs as lifelong chronic disease medications rather than short-term weight loss interventions, the cost, adherence, and long-term access challenges in the US GLP-1 market in 2026 become all the more urgent to solve.
GLP-1 Ozempic Global & US Market Outlook Statistics 2026
| Market Outlook Category | Data Point | Source |
|---|---|---|
| Global GLP-1 receptor agonist market (2024) | $53.46 billion | Grand View Research |
| Global GLP-1 receptor agonist market (2030 projection) | $156.71 billion (CAGR 17.46%) | Grand View Research |
| Global GLP-1 drugs market (2026) | $58.05 billion | Towards Healthcare |
| Global GLP-1 drugs market (2035 projection) | $132.79 billion (CAGR 9.63%) | Towards Healthcare |
| Global obesity GLP-1 market (2025) | $8.21 billion | Precedence Research, Feb 2026 |
| Global obesity GLP-1 market (2035 projection) | $66.57 billion (CAGR 23.28%) | Precedence Research, Feb 2026 |
| US obesity GLP-1 market size (2025) | $3.69 billion | Precedence Research, Feb 2026 |
| US obesity GLP-1 market projection (2035) | ~$30.41 billion (CAGR 23.48% from 2026–2035) | Precedence Research, Feb 2026 |
| North America share of global GLP-1 weight loss market (2024) | 75.50% | Grand View Research |
| Ozempic brand share of GLP-1 agonist market (2025) | 37.77% — largest single brand | Grand View Research |
| Semaglutide (all brands) share of GLP-1 weight loss market (2024) | 60.70% | Grand View Research |
| Parenteral (injectable) GLP-1 share of market (2025) | 92.58% of all GLP-1 product revenue | Grand View Research |
| Retail pharmacy distribution share (2024–2025) | ~55–60% of GLP-1 sales via retail pharmacies | Grand View Research |
| Pfizer Phase 2b GLP-1 trial results (Feb 2026) | Positive results for ultra-long-acting monthly injectable GLP-1 (PF-08653944) | Precedence Research, citing Businesswire, Feb 2026 |
| AI-designed GLP-1 peptide sequences (June 2025) | ImmunoPrecise Antibodies launched AI-designed GLP-1RA sequences showing results comparable or superior to semaglutide | Businesswire, June 2025 |
| Two major pharmaceutical companies dominating global market | Novo Nordisk (Denmark) and Eli Lilly (US) control the majority of the global GLP-1 market | Industry consensus |
Source: Grand View Research; Towards Healthcare; Precedence Research (February 2026); Businesswire (June 2025, February 2026); Creo Clinic / Novo Nordisk
The global GLP-1 market outlook heading into the second half of 2026 and beyond is defined by both extraordinary opportunity and genuine uncertainty. The convergence of multiple forecast ranges — from $132.79 billion (Towards Healthcare) to $156.71 billion (Grand View Research) by the early-to-mid 2030s — reflects different methodologies and product scope definitions, but all projections point in the same direction: sustained, double-digit compound annual growth for at least the next decade. The 23.28% projected CAGR for the global obesity GLP-1 segment is particularly striking, suggesting that the weight management side of the market — still younger and smaller than the diabetes side — will grow faster than the overall category as insurance coverage expands and oral formulations gain regulatory traction.
The competitive landscape is also shifting in ways that could reshape the market. Pfizer’s February 2026 announcement of positive Phase 2b results for its ultra-long-acting monthly injectable GLP-1 (PF-08653944) — a drug that would require only once-monthly dosing compared to once-weekly for Ozempic — signals that the duopoly currently held by Novo Nordisk and Eli Lilly is entering a new phase of competitive pressure. Similarly, the AI-designed GLP-1 receptor agonist peptide sequences announced by ImmunoPrecise Antibodies in June 2025 — showing in-vitro results comparable or superior to semaglutide — hint at a future where next-generation GLP-1 compounds are developed at a pace and scale that traditional pharmaceutical R&D cannot match alone. As 2026 unfolds, the GLP-1 and Ozempic market is not simply growing — it is being actively reinvented.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
